+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
MALE
ID07711002

Randomized Study of Saruparib with Physicians Choice of Androgen Receptor Pathway Inhibitor in Men with Metastatic Hormone-Sensitive Prostate Cancer Previously Treated with Docetaxel or PSMA-Directed Lutetium Therapy

Led by AstraZeneca · Updated on 2026-10-15

1330

Participants Needed

210

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of saruparib combined with a physicians choice of androgen receptor pathway inhibitors ARPI compared with a placebo plus ARPI in men who have metastatic hormone-sensitive prostate cancer mHSPC. These men have previously been treated with docetaxel chemotherapy or PSMA-directed lutetium-177 radioligand therapy and show no signs of disease progression, with PSA levels equal to or above 0.2 ngmL. This phase III randomized study aims to measure the impact of these treatments on disease progression. Participants receive either saruparib 60 mg orally once daily along with a chosen ARPI enzalutamide, darolutamide, or abiraterone in 28-day cycles or a placebo plus the same ARPI regimen in similar cycles. The study is double-blind and includes two cohorts, comparing the combined use of saruparib and ARPI against placebo and ARPI. Treatment continues under medical supervision with regular monitoring. During the study, participants undergo evaluations to measure radiographic progression-free survival up to approximately 56 months, along with other outcomes such as overall survival, time to progression, symptomatic skeletal events, PSA progression, and physical function changes. Blood samples and tumor tissue are collected for biomarker analysis. Safety and treatment effects are closely monitored throughout the study, which may last several years.

CONDITIONS

Brief Title

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here